LENZ THERAPEUTICS, INC. Investment Income, Interest
LENZ THERAPEUTICS, INC. (LENZ) reported Investment Income, Interest of $2.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $2.27M, a 1.07% increase year-over-year.
- LENZ THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $2.64M, a 13.82% increase year-over-year.
- LENZ THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $2.99M, a 16.37% increase year-over-year.
- LENZ THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $2.20M, a 19.55% decline year-over-year.
- LENZ THERAPEUTICS, INC. investment income, interest for fiscal 2025 was $9.76M, a 14.07% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $8.55M, a 290.73% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $2.19M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.27M 10-Q · filed 2026-08-11 | $4.91M 10-Q · filed 2026-08-11 | $7.90M derived: sum of 3 quarters · filed 2026-08-11 | $10.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.64M 10-Q · filed 2026-05-11 | $5.63M derived: sum of 2 quarters · filed 2026-05-11 | $7.83M derived: sum of 3 quarters · filed 2026-05-11 | $10.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $5.19M derived: sum of 2 quarters · filed 2026-03-24 | $7.43M derived: sum of 3 quarters · filed 2026-08-11 | $9.76M 10-K · filed 2026-03-24 |
| 2025-09-30 | $2.20M 10-Q · filed 2025-11-05 | $4.45M derived: sum of 2 quarters · filed 2026-08-11 | $6.77M 10-Q · filed 2025-11-05 | $9.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.25M 10-Q · filed 2026-08-11 | $4.57M 10-Q · filed 2026-08-11 | $7.13M derived: sum of 3 quarters · filed 2026-08-11 | $9.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.32M 10-Q · filed 2026-05-11 | $4.89M derived: sum of 2 quarters · filed 2026-05-11 | $7.63M derived: sum of 3 quarters · filed 2026-05-11 | $10.09M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $5.30M derived: sum of 2 quarters · filed 2026-03-24 | $7.76M derived: sum of 3 quarters · filed 2026-03-24 | $8.55M 10-K · filed 2026-03-24 |
| 2024-09-30 | $2.74M 10-Q · filed 2025-11-05 | $5.20M derived: sum of 2 quarters · filed 2025-11-05 | $5.99M 10-Q · filed 2025-11-05 | $6.84M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $2.46M 10-Q · filed 2025-07-30 | $3.25M 10-Q · filed 2025-07-30 | $4.10M derived: sum of 3 quarters · filed 2025-07-30 | $5.19M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $788.00K 10-Q · filed 2025-05-07 | $1.64M derived: sum of 2 quarters · filed 2025-05-07 | $2.73M derived: sum of 3 quarters · filed 2025-05-07 | $2.98M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $851.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.94M derived: sum of 2 quarters · filed 2025-03-19 | $2.19M derived: sum of 3 quarters · filed 2025-03-19 | $2.19M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.09M 10-Q · filed 2024-11-06 | $1.34M derived: sum of 2 quarters · filed 2024-11-06 | $1.34M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $251.00K 10-Q · filed 2024-08-14 | $252.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |